Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With EGFR Mutation”

728 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 728 results

Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07360743
What this trial is testing

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Who this might be right for
Non Small Cell Lung Cancer (Squamous or Non Squamous)
UNICANCER 275
Large-scale testing (Phase 3)UnknownNCT02001896
What this trial is testing

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Xinjiang Medical University 60
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)Not Yet RecruitingNCT07416994
What this trial is testing

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT01542437
What this trial is testing

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFRHER-2
Instituto Nacional de Cancerologia de Mexico 66
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Testing effectiveness (Phase 2)Study completedNCT01588145
What this trial is testing

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 273
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Study completedNCT03434418
What this trial is testing

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Duke University 17
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Not applicableUnknownNCT00815971
What this trial is testing

Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib

Who this might be right for
Non-Small Cell Lung Cancer
Aarhus University Hospital 300
Early research (Phase 1)Study completedNCT00993499
What this trial is testing

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644
What this trial is testing

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 44
Load More Results